A new Flag­ship start­up looks to crack tR­NA bi­ol­o­gy in search for com­plete­ly new class of ther­a­peu­tics

4 years ago
Financing
Startups

Bio­gen in­ves­ti­gates a death pos­si­bly linked to its con­tro­ver­sial new Alzheimer's drug

4 years ago
Pharma

Mi­rati sees more re­spons­es for KRAS drug in Keytru­da com­bo as it an­gles for an edge over Am­gen

4 years ago
R&D

Ko­re­an reg­u­la­tors shut down Sam­sung Phar­ma man­u­fac­tur­ing af­ter find­ing ad­di­tives, false records

4 years ago
Manufacturing

'We were wrong': Af­ter ush­er­ing Mer­ck KGaA in­to PD-(L)1 fren­zy, on­col­o­gy chief jumps on mis­sion to 'tur­bocharge' T ...

4 years ago
Financing
Cell/Gene Tx

AI up­start grabs $40M launch round; Sanofi backs a gene ther­a­py play­er; Ax­some hits a snag at the FDA

4 years ago
News Briefing

Small biotech chaired by ex-Pur­due CEO Mark Tim­ney jumps in­to the SPAC lane

4 years ago
Financing

Covid-19 roundup: Re­gen­eron/Roche an­ti­body com­bo keeps its punch 8 months in; WaPo: Pfiz­er ex­pect­ed to seek ...

4 years ago
Coronavirus

Bris­tol My­ers adds to neoad­ju­vant win for Op­di­vo in lung can­cer, es­ca­lat­ing ear­ly can­cer show­down with Mer­ck

4 years ago
R&D
Pharma

A Bloomberg-backed can­cer drug sum­mit aims to thaw US-Chi­na re­la­tions

4 years ago
China
Pharma

Ab­bott plots new paths to clin­i­cal tri­al di­ver­si­ty, join­ing bio­phar­ma push for broad­er in­clu­sion

4 years ago
Pharma
Marketing

Seagen and Dai­ichi are duk­ing it out over the link­ers used in some block­buster drug plays. Could that af­fect a ...

4 years ago
Pharma

John Maraganore steps in­to a new role at an up­start biotech as the god­fa­ther phase of his ca­reer takes shape

4 years ago
Bioregnum
Cell/Gene Tx

Steer­ing clear of Fi­bro­Gen/As­traZeneca wreck­age, Glax­o­SmithK­line spot­lights piv­otal da­ta for star ane­mia drug

4 years ago
R&D

Mixed court de­ci­sions for No­var­tis in DC and Sanofi, No­vo Nordisk in NJ fur­ther com­pli­cate whose in­ter­pre­ta­tion of ...

4 years ago
R&D
Pharma

They had promis­ing gene ther­a­pies for their daugh­ter's ul­tra-rare dis­ease. But how to tell if one worked?

4 years ago
Cell/Gene Tx
In Focus

Black­stone dou­bles down on cell ther­a­py, pour­ing life (and a lot of cash) in­to a once hot biotech

4 years ago
Deals
Cell/Gene Tx

Pfiz­er's Covid pill de­liv­ers; All you need to know about Dem­s' drug pric­ing plan; What else can an­ti­sense do?; and ...

4 years ago
Weekly

House Over­sight Com­mit­tee digs in on McK­in­sey's con­flict­ing ties with FDA, opi­oids, and block­ing Hu­mi­ra com­peti­tors

4 years ago
Pharma
FDA+

San Fran biotech gets an­oth­er blow to lead drug; Swiss biotech rais­es $49 mil­lion in Se­ries A — with help from big ...

4 years ago
News Briefing

Cell ther­a­py start­up bit.bio adds $100M+ to its cof­fers and some im­pres­sive names to its board of di­rec­tors

4 years ago
Financing

Dem­s' $100B deal re­duced fur­ther: Medicare drug price ne­go­ti­a­tions pushed to 13 years for bi­o­log­ics

4 years ago
Pharma
FDA+

De­ci­pher­a's TKI drug flops key test in ear­li­er-line GI tu­mors, send­ing stock in­to a tail­spin

4 years ago
R&D

A pair of Eu­ro­pean biotechs hit be­low their mark as close of 2021 biotech IPO mar­ket chugs a lit­tle bit slow­er

4 years ago
Financing
First page Previous page 617618619620621622623 Next page Last page
A service from the Financial Times